

# Gillian M Duchesne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3539964/publications.pdf>

Version: 2024-02-01

102  
papers

4,145  
citations

126907

33  
h-index

114465

63  
g-index

106  
all docs

106  
docs citations

106  
times ranked

3842  
citing authors

#	ARTICLE	IF	CITATIONS
1	Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. <i>Pathology</i> , 2022, 54, 49-54.	0.6	7
2	Navigating uncertainty: The implementation of Australian radiation therapy advanced practitioners. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2021, 17, 82-88.	1.9	6
3	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQq1 1 0.784314 rgBT /Overlock 2020, 21, 1331-1340.	10.7	197
4	Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 693-702.	0.8	48
5	Effective and well tolerated: where do these drugs fit now?. <i>Lancet Oncology</i> , The, 2019, 20, 469-470.	10.7	0
6	Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. <i>Lancet Oncology</i> , The, 2019, 20, 267-281.	10.7	84
7	Extracting tumour prognostic factors from a diverse electronic record dataset in genito-urinary oncology. <i>International Journal of Medical Informatics</i> , 2019, 121, 53-57.	3.3	9
8	Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 549-557.	1.3	4
9	Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 739-746.	1.3	5
10	Trans Tasman Radiation Oncology Group Cancer Research: Phase III " Muscle Invasive Bladder Cancer trial (TROG 02.03): A moral dilemma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 668-670.	1.8	1
11	Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients. <i>Prostate International</i> , 2017, 5, 8-12.	2.3	7
12	Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1192-1201.	10.7	45
13	Patterns of health services utilization in the last two weeks of life among cancer patients: Experience in an Australian academic cancer center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 400-406.	1.1	8
14	Timing of androgen-deprivation therapy in prostate cancer " Author's reply. <i>Lancet Oncology</i> , The, 2017, 18, e635.	10.7	0
15	Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06) Tj ETQq1 1 0.784314 rgBT /Ove The, 2016, 17, 727-737.	10.7	172
16	Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. <i>Radiotherapy and Oncology</i> , 2016, 121, 98-102.	0.6	33
17	Testing the <sc>A</sc>ssessment of <sc>N</sc>ew <sc>R</sc>adiation <sc>O</sc>ncology <sc>T</sc>echnology and <sc>T</sc>reatments framework using the evaluation of postâ€prostatectomy radiotherapy techniques. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 129-137.	1.8	2
18	Timing of androgen-deprivation therapy for prostate cancer: still a long way to go " Authors' reply. <i>Lancet Oncology</i> , The, 2016, 17, e313-e314.	10.7	1

#	ARTICLE	IF	CITATIONS
19	Nurse-led group consultation intervention reduces depressive symptoms in men with localised prostate cancer: a cluster randomised controlled trial. <i>BMC Cancer</i> , 2016, 16, 637.	2.6	26
20	Development of the Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) framework. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 363-370.	1.8	12
21	Cognitive existential couple therapy (CECT) in men and partners facing localised prostate cancer: a randomised controlled trial. <i>BJU International</i> , 2015, 115, 35-45.	2.5	31
22	Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. <i>Radiotherapy and Oncology</i> , 2015, 115, 301-307.	0.6	52
23	In Reply to Jenkins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 243.	0.8	0
24	Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer. <i>BJU International</i> , 2014, 114, 344-353.	2.5	26
25	The Timing of Androgen-Deprivation therapy in incurable prostate cancer™ protocol (TOAD) - where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans-Tasman Radiation Oncology Group 03.06 clinical trial. <i>BJU International</i> , 2014, 114, 9-12.	2.5	4
26	A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. <i>Radiotherapy and Oncology</i> , 2014, 112, 187-193.	0.6	19
27	Around the Globe – Radiation Oncology in Australia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1-6.	0.8	9
28	Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: Correlation with histopathology. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 439-448.	1.8	8
29	Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. <i>Lancet Oncology</i> , The, 2014, 15, 1076-1089.	10.7	121
30	Practical implementation of an existing smoking detection pipeline and reduced support vector machine training corpus requirements. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 27-30.	4.4	12
31	Researching Depression in Prostate Cancer Patients: Factors, Timing, and Measures. <i>Journal of Men's Health</i> , 2014, 11, 145-156.	0.3	2
32	Cognitive Existential Couple Therapy for newly diagnosed prostate cancer patients and their partners: a descriptive pilot study. <i>Psycho-Oncology</i> , 2013, 22, 465-469.	2.3	20
33	The Impact of Implant Position Verification Using Gold Fiducials on Urethral Toxicity in Patients with Prostate Cancer Treated with High-Dose-Rate Brachytherapy. <i>Brachytherapy</i> , 2013, 12, S70.	0.5	0
34	Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning. <i>Brachytherapy</i> , 2013, 12, 628-636.	0.5	30
35	Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 107, 140-146.	0.6	52
36	Direct 2-Arm Comparison Shows Benefit of High-Dose-Rate Brachytherapy Boost vs External Beam Radiation Therapy Alone for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 679-685.	0.8	90

#	ARTICLE	IF	CITATIONS
37	Quality improvements in prostate radiotherapy: Outcomes and impact of comprehensive quality assurance during the <scp>TROG</scp> 03.04 â€ˆ<scp>RADAR</scp>â€™™ trial. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 247-257.	1.8	36
38	Australasian brachytherapy audit: Results of the â€ˆendâ€™toâ€™endâ€™™ dosimetry pilot study. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 490-498.	1.8	13
39	Patterns of retreatment with radiotherapy in a large academic centre. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 610-616.	1.8	10
40	A randomised, doubleâ€™blind, placeboâ€™controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 81-88.	1.8	28
41	High-Dose-Rate Brachytherapy as a Monotherapy for Favorable-Risk Prostate Cancer: A Phase II Trial. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1889-1896.	0.8	107
42	Benchmarking Dosimetric Quality Assessment of Prostate Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 998-1005.	0.8	11
43	Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncology, The, 2012, 13, 1260-1270.	10.7	49
44	Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiotherapy and Oncology, 2012, 105, 184-192.	0.6	39
45	Seminal vesicle interfraction displacement and margins in image guided radiotherapy for prostate cancer. Radiation Oncology, 2012, 7, 139.	2.7	35
46	Imaging, radiation oncology and randomised trials: Time for a change?. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 97-100.	1.8	2
47	Another form of subgroup to beware. Radiotherapy and Oncology, 2011, 101, 525-526.	0.6	1
48	Online Adaptive Radiotherapy for Muscle-Invasive Bladder Cancer: Results of a Pilot Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 765-771.	0.8	108
49	Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiation Oncology, 2011, 6, 145.	2.7	73
50	A Comparison of the Prognostic Value of Early PSA Test-Based Variables Following External Beam Radiotherapy, With or Without Preceding Androgen Deprivation: Analysis of Data From the TROG 96.01 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2011, 79, 385-391.	0.8	34
51	Predictors of Androgen Deprivation Therapy Efficacy Combined With Prostatic Irradiation: The Central Role of Tumor Stage and Radiation Dose. International Journal of Radiation Oncology Biology Physics, 2011, 79, 724-731.	0.8	15
52	Interfraction Prostate Rotation Determined from In-Room Computerized Tomography Images. Medical Dosimetry, 2011, 36, 188-194.	0.9	29
53	High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy, 2010, 9, 27-35.	0.5	72
54	Development and evaluation of a training program for therapeutic radiographers as a basis for online adaptive radiation therapy for bladder carcinoma. Radiography, 2010, 16, 14-20.	2.1	38

#	ARTICLE	IF	CITATIONS
55	A Comparison of In-Room Computerized Tomography Options for Detection of Fiducial Markers in Prostate Cancer Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1248-1256.	0.8	10
56	Tribulations of a prostate cancer trial â€“ Lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2010, 54, 508-511.	1.8	3
57	A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. <i>BMC Cancer</i> , 2009, 9, 419.	2.6	32
58	Online Kidney Position Verification Using Non-Contrast Radiographs on a Linear Accelerator with on Board KV X-Ray Imaging Capability. <i>Medical Dosimetry</i> , 2009, 34, 293-300.	0.9	0
59	Comparison of CT on Rails With Electronic Portal Imaging for Positioning of Prostate Cancer Patients With Implanted Fiducial Markers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 906-912.	0.8	21
60	An in vivo investigative protocol for HDR prostate brachytherapy using urethral and rectal thermoluminescence dosimetry. <i>Radiotherapy and Oncology</i> , 2009, 91, 243-248.	0.6	35
61	Is there more than one proctitis syndrome? A revisit using data from the TROG 96.01 trial. <i>Radiotherapy and Oncology</i> , 2009, 90, 400-407.	0.6	70
62	PSA response signatures â€“ a powerful new prognostic indicator after radiation for prostate cancer?. <i>Radiotherapy and Oncology</i> , 2009, 90, 382-388.	0.6	17
63	Assuring high quality treatment delivery in clinical trials â€“ Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 â€œRADARâ€•set-up accuracy study. <i>Radiotherapy and Oncology</i> , 2009, 90, 299-306.	0.6	35
64	Urethral stricture following high dose rate brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2009, 91, 232-236.	0.6	139
65	Coping Patterns and Psychosocial Distress in Female Partners of Prostate Cancer Patients. <i>Psychosomatics</i> , 2009, 50, 375-382.	2.5	25
66	The Detectability and Localization Accuracy of Implanted Fiducial Markers Determined on In-Room Computerized Tomography (CT) and Electronic Portal Images (EPI). <i>Medical Dosimetry</i> , 2008, 33, 226-233.	0.9	15
67	Correlation of a bioeffect model with tumor control in localized prostate cancer treated with low-dose-rate brachytherapy. <i>Brachytherapy</i> , 2008, 7, 189.	0.5	0
68	Percentage of Biopsy Cores Positive for Malignancy and Biochemical Failure Following Prostate Cancer Radiotherapy in 3,264 Men: Statistical Significance Without Predictive Performance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1169-1175.	0.8	24
69	Corrigendum to â€œEfficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Groupâ€•[ <i>Radiother Oncol</i> 81 (2006) 9â€“17]. <i>Radiotherapy and Oncology</i> , 2007, 83, 215.	0.6	1
70	Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results. <i>Radiotherapy and Oncology</i> , 2007, 84, 128-134.	0.6	60
71	Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the $\hat{\mu}/\hat{\sigma}^2$ Ratio of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 24-33.	0.8	153
72	Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. <i>Radiotherapy and Oncology</i> , 2006, 81, 9-17.	0.6	70

#	ARTICLE	IF	CITATIONS
73	The psychosocial impact of prostate cancer on patients and their partners. <i>Medical Journal of Australia</i> , 2006, 185, 428-432.	1.7	115
74	Psychosocial adjustment of female partners of men with prostate cancer: a review of the literature. <i>Psycho-Oncology</i> , 2006, 15, 937-953.	2.3	197
75	A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?. <i>Brachytherapy</i> , 2006, 5, 256-261.	0.5	14
76	An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 351-357.	0.8	31
77	How Early Is Early: Androgen Deprivation for Prostate-Specific Antigen Relapse in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2964-2964.	1.6	2
78	Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants. <i>Brachytherapy</i> , 2005, 4, 146-153.	0.5	11
79	Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. <i>Lancet Oncology</i> , 2005, 6, 841-850.	10.7	351
80	Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. <i>Radiotherapy and Oncology</i> , 2005, 77, 117-125.	0.6	47
81	Trends in the use of androgen deprivation in prostate cancer. <i>Acta Oncologica</i> , 2004, 43, 382-387.	1.8	5
82	What defines intermediate-risk prostate cancer? Variability in published prognostic models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 11-18.	0.8	18
83	Assessment of i-125 prostate implants by tumor bioeffect. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 1405-1413.	0.8	25
84	Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1082-1087.	0.8	30
85	Prostate implant evaluation using tumour control probability—the effect of input parameters. <i>Physics in Medicine and Biology</i> , 2004, 49, 3649-3664.	3.0	18
86	Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2004, 73, 33-38.	0.6	52
87	What to do for prostate cancer patients with a rising PSA—a survey of Australian practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 986-991.	0.8	27
88	Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. <i>Radiotherapy and Oncology</i> , 2003, 68, 255-267.	0.6	33
89	Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. <i>Urology</i> , 2003, 61, 179-183.	1.0	20
90	Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: Influence of V150 and V200 parameters. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2002, 46, 384-389.	0.6	17

#	ARTICLE	IF	CITATIONS
91	Measurement of lung tumor volumes using three-dimensional computer planning software. International Journal of Radiation Oncology Biology Physics, 2002, 53, 566-573.	0.8	88
92	Radiation for prostate cancer. Lancet Oncology, The, 2001, 2, 73-81.	10.7	13
93	Carcinoid tumour of the orbital muscles: A rare occurrence. Journal of Medical Imaging and Radiation Oncology, 2001, 45, 179-181.	0.6	23
94	A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. International Journal of Radiation Oncology Biology Physics, 2000, 47, 379-388.	0.8	127
95	Your questions to the PBAC: Prescriptions for flutamide and bicalutamide. Australian Prescriber, 1999, 22, 99.	1.0	0
96	Management of localised prostate cancer: state of the art. Medical Journal of Australia, 1998, 169, 11-12.	1.7	19
97	Identification of intermediate-risk prostate cancer patients treated with radical radiotherapy suitable for neoadjuvant hormone studies. Radiotherapy and Oncology, 1996, 38, 7-12.	0.6	26
98	Reversible changes in radiation response induced by all-trans retinoic acid. International Journal of Radiation Oncology Biology Physics, 1995, 33, 875-880.	0.8	7
99	Oncology and nuclear medicine: a developing collaboration. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1229-1231.	2.1	2
100	Fundamental bases of combined therapy in lung cancer: cell resistance to chemotherapy and radiotherapy. Lung Cancer, 1994, 10, S67-S72.	2.0	17
101	The dose-rate effect in human tumour cells. Radiotherapy and Oncology, 1987, 9, 299-310.	0.6	257
102	Better Understanding the Timing of Androgen Deprivation (TOAD) Trial Outcomes: Impacts of Prior ADT. JNCI Cancer Spectrum, 0, , .	2.9	0